Corey Langer


Affiliation: Fox Chase Cancer Center
Country: USA


  1. request reprint
    Langer C, Choy H, Glaspy J, Colowick A. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer. 2002;95:613-23 pubmed
    ..The introduction of darbepoetin-alpha into clinical practice may overcome some of the limitations of current treatments and facilitate improvement in the management of cancer-related anemia. ..
  2. request reprint
    Langer C. Irinotecan/Taxane combinations in advanced non-small-cell lung cancer. Clin Lung Cancer. 2002;4 Suppl 1:S10-4 pubmed
    ..Ongoing and future trials will further clarify the role of irinotecan/taxane combinations in the treatment of NSCLC, both in treatment-naive patients and in the second-line setting...
  3. request reprint
    Langer C. Neglected and underrepresented subpopulations: elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2006;7 Suppl 4:S126-37 pubmed
    ..Future efforts will need to differentiate the reasons for compromised PS, be it tumor burden, comorbidity, or both...
  4. request reprint
    Langer C. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer. 2004;6 Suppl 2:S85-8 pubmed
    ..These Selective Targeting for Efficacy in Lung Cancer, Lower Adverse Reaction (STELLAR) trials represent the largest randomized phase III programs in patients with NSCLC and a poor performance status...
  5. request reprint
    Langer C. The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancer. Clin Lung Cancer. 2003;4 Suppl 2:S45-9 pubmed
    ..Whether gemcitabine in combination with radiation, with or without other agents, will ultimately prove superior to standard chemoradiation regimens remains to be determined...